Olanzapine-containing antiemetic therapy for the prevention of carboplatin-induced nausea and vomiting
| Autor: | Tomohiro Uto, Takafumi Suda, Shun Matsuura, Kazuhiro Asada, K. Tanaka, Naoki Inui, Tomoyuki Fujisawa, Noriyuki Enomoto, Hideki Yasui, Yuzo Suzuki, Masato Karayama, Kazuki Furuhashi, Hideki Kusagaya, Dai Hashimoto, Takashi Matsui, Yutaro Nakamura, Hironao Hozumi |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Male
0301 basic medicine Olanzapine Cancer Research medicine.medical_specialty Lung Neoplasms Vomiting Nausea medicine.drug_class medicine.medical_treatment Antineoplastic Agents Toxicology Gastroenterology Dexamethasone Carboplatin 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Internal medicine Humans Medicine Antiemetic Pharmacology (medical) Prospective Studies Aprepitant Aged Aged 80 and over Pharmacology Chemotherapy business.industry Middle Aged 030104 developmental biology Oncology chemistry 030220 oncology & carcinogenesis Antiemetics Drug Therapy Combination Female medicine.symptom business Chemotherapy-induced nausea and vomiting medicine.drug |
| Zdroj: | Cancer Chemotherapy and Pharmacology. 84:147-153 |
| ISSN: | 1432-0843 0344-5704 |
| Popis: | There remains an unmet clinical need for the control of chemotherapy-induced nausea and vomiting (CINV), particularly in the prevention of nausea and the delayed phase control. We evaluated the efficacy and safety of antiemetic therapy with olanzapine, a neurokinin-1 receptor antagonist, a 5-hydroxytryptamine-3 (5-HT3) receptor antagonist and dexamethasone in patients receiving carboplatin-containing chemotherapy. Olanzapine inhibits signalling via multiple neurotransmitter receptors involved in CINV. Chemotherapy-naive patients with lung cancer who received carboplatin-containing chemotherapy were enrolled in this phase-II study. Patients received olanzapine, aprepitant, a 5-HT3 receptor antagonist and dexamethasone. The primary endpoint was the complete response rate (no vomiting and no rescue therapy) during 120 h after administration of chemotherapy agents. Thirty-three patients received olanzapine-containing antiemetic therapy. The overall complete response rate was 93.3% (95% confidence interval, 80.4–98.3%). The frequency of nausea was 15.2% in the delayed phase and 18.2% in the overall phase. Somnolence was observed in 16 patients. Adding olanzapine to antiemetic therapy with aprepitant, a 5-HT3 receptor antagonist and dexamethasone improved CINV control in patients receiving carboplatin-containing chemotherapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink